FAIR VALUE - Acquired (Details)		1 Months Ended	12 Months Ended
	Jul. 21, 2022 USD ($)	Apr. 30, 2021 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Finite-lived intangible gross carrying amount			$ 497,332,000	$ 480,915,000
Research and development			34,286,000	22,318,000	$ 11,369,000
Inventories			111,196,000	105,355,000
Raw materials			62,237,000	67,726,000
Finished goods			36,198,000	28,020,000
Intangible asset impairment charge			0	112,000	$ 2,374,000
Acquired ANDA intangible assets
Finite-lived intangible gross carrying amount			209,780,000	195,862,000
Intangible asset impairment charge			0	100,000
Oakrum Pharma
Useful life of intangible assets	7 years
Intangible asset impairment charge			0
Oakrum Pharma | Acquired ANDA intangible assets
Total asset purchase	$ 8,000,000
Contingent liability not recognized, asset acquisition	200,000
Finite-lived intangible gross carrying amount	7,200,000
Research and development	$ 1,200,000
Useful life of intangible assets	7 years
Oakrum Pharma | Acquired ANDA intangible assets | Measurement Input, Discount Rate
Intangible asset measurement input	13
Sandoz
Total asset purchase		$ 20,700,000
Transaction costs		400,000
Finite-lived intangible gross carrying amount		11,400,000
Inventories		9,700,000
Raw materials		600,000
Sample inventory		1,000,000
Finished goods		$ 8,100,000
Useful life of intangible assets		7 years
Intangible asset impairment charge			$ 0	$ 0
Sandoz | Measurement Input, Discount Rate
Intangible asset measurement input		10